Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Roche collaborates with Ibex and Amazon Web to improve cancer diagnosis

Integrated artificial intelligence-based tools will support clinicians’ decisions in cancer diagnosis

- PMLiVE

University of Oxford launches new trial to enhance flu and COVID-19 vaccines

Results from the study are expected to help increase the protection of future vaccines

- PMLiVE

The impact of cell therapies on cancer treatments

PME talks to Matt Angel, CEO of Eterna Therapeutics, about how research using cell therapies to treat cancer has improved in the last decade, and how these therapies benefit patients

Create Long-lasting KOL Relationships, benefits of virtual advisory boards

Here's another top reason why virtual advisory boards are simply better than in-person and hybrid advisory boards. #4. More Frequent Interactions and Long-lasting KOL Relationships Another important benefit of online...

Impetus Digital

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

EU flag

EMA announces latest action to address critical medicine shortages in EU

The documents will support Member States to collaboratively address shortages

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

ICR experts develop clinical trial guidelines to support future research

The new guidance documents are expected to transform dose-finding trials

- PMLiVE

Coming of age

People are investing in longevity… and by ‘people’, I mean profit-seekers

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

- PMLiVE

GSK’s RSV vaccine Arexvy shows promise in adults aged 50 to 59 years

Arexvy has already been approved in the US and Europe to protect those aged 60 years and older

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links